KALV Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 105696 min ago

@ $14.93

Išleistas: 14 vas. 2024 @ 21:24

Grąža: -27.77%

Ankstesnis signalas: vas. 14 - 19:07

Ankstesnis signalas: Pardavimas

Grąža: -1.62 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs...

Stats
Šios dienos apimtis	233 587
Vidutinė apimtis	814 547
Rinkos kapitalizacija	454.79M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $-0.690 ) 2024-07-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.46
ATR14	$0.0170 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Fairey William	Buy	17 000	Stock Option (Right to Buy)
2024-04-18	Fairey William	Buy	0
2024-03-06	Palleiko Benjamin L	Buy	250 000	Restricted Stock Unit
2024-02-20	Venrock Healthcare Capital Partners Iii, L.p.	Buy	655 738	Pre-Funded Warrants (Right to Buy)
2024-02-17	Feener Edward P.	Buy	18 788	Common Stock

INSIDER POWER
66.06
Last 98 transactions
Buy: 3 056 025 \| Sell: 628 012

Tūris Koreliacija

Ilgas: 0.33 (neutral)

Trumpas: 0.30 (neutral)

Signal:(58.845) Neutral

Kalvista Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ACLS	0.953
BWMN	0.951
NVCN	0.949
NVAC	0.947
CRUS	0.947
TETC	0.947
XFIN	0.946
FOCS	0.944
JMAC	0.943
GENQ	0.941

10 Labiausiai neigiamai susiję koreliacijos
NAKD	-0.955
AMGN	-0.935
THMA	-0.932
BHTG	-0.93
LGMK	-0.926
PCSA	-0.925
AHPI	-0.924
TRIT	-0.918
CREG	-0.911
PLIN	-0.907

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Kalvista Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.07
( neutral )

-0.06
( neutral )

0.00
( neutral )

0.02
( neutral )

0.00
( neutral )

0.09
( neutral )

Kalvista Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-802 000 (0.00 %)
EPS:	$-2.68

FY	2023
Pajamos:	$0
Bruto pelnas:	$-802 000 (0.00 %)
EPS:	$-2.68

FY	2022
Pajamos:	$0
Bruto pelnas:	$-743 000 (0.00 %)
EPS:	$-2.80

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.42

Financial Reports:

No articles found.

Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.